# A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

> **NCT01670513** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Dow Pharmaceutical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** IDP-118 Low Strength
- **DRUG:** IDP-118 High Strength

## Key facts

- **NCT ID:** NCT01670513
- **Lead sponsor:** Dow Pharmaceutical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2013-05
- **Final completion:** 2013-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670513, "A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01670513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*